Main randomized clinical trials investigating ovarian function suppression in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) in premenopausal women with hormone receptor-positive early breast cancer. The gene discussed is CYP19A1; the disease is breast cancer.